Lv2
180 积分 2024-07-23 加入
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials
7天前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
8天前
已完结
Strategies for targeting cytokines in inflammatory bowel disease
10天前
已完结
Masking T cell engagers mitigates on-target off-tumor activity
18天前
已完结
Interleukin-18 armours antitumour immune effectors
1个月前
已完结
IL-21 Enhances and Sustains CD8+ T Cell Responses to Achieve Durable Tumor Immunity: Comparative Evaluation of IL-2, IL-15, and IL-21
1个月前
已完结
An engineered IL-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with PD-1 or TIGIT blockade
1个月前
已完结
Interleukin-21: a double-edged sword with therapeutic potential
1个月前
已完结
Identification and characterization of an antagonistic anti-mouse CD40 antibody
1个月前
已关闭
Advances in the treatment of systemic lupus erythematosus
2个月前
已完结
皖公网安备34019202002308
